Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of ...

Insilico Medicine ("Insilico"), a clinical-stage, generative AI-driven drug discovery company, today announced the ...